Sutro Biopharma, Inc.
$15.38
-$0.22 (-1.41%)
$15.25Day Range$16.13
Key Statistics
Market Cap
$258.67M
Shares Outstanding
16.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 27, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$15.94
Day High
$16.13
Day Low
$15.25
Volume
216.5K
VWAP
$15.56
Prev Close
$15.60
Transactions
--
Acc. Volume
--
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836128 employees111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080650-392-8412IPO Sep 27, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001382101
- Composite FIGI
- BBG000R4V3P3
- Share Class FIGI
- BBG001T94MP6
- Ticker Root
- STRO
- SIC Code
- 2836
About Sutro Biopharma, Inc. (STRO) Stock
Sutro Biopharma, Inc. (STRO) closed the 2026-09-17 session at $15.38, down 1.41% versus the previous close (-0.22). The stock opened at $15.94 and traded between $15.25 and $16.13 during that session. Session trading volume was 217K shares. The volume-weighted average price (VWAP) is $15.56.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma, Inc. has a market capitalization of $258.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. STRO is listed on the XNAS exchange. The company employs approximately 128 people. Sutro Biopharma, Inc. is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2018-09-27.
On this page you can find market STRO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.